Long-term follow-up analysis of 100 patients with splenic marginal zone lymphoma treated with splenectomy as first-line treatment

References

• Swerdlow S, Harris N, Jaffe E, et al. WHO classification of tumours of haematopoietic and lymphoid tissue. Lyon: IARC; 2008.
   Google Scholar
• Thieblemont C, Felman P, Callet-Bauchu E, et al. Splenic marginal-zone lymphoma: a distinct clinical and pathological entity. Lancet Oncol 2003;4:95–103.
   PubMed Web of Science ®Google Scholar
• Parry-Jones N, Matutes E, Gruszka-Westwood AM, et al. Prognostic features of splenic lymphoma with villous lymphocytes: a report on 129 patients. Br J Haematol 2003;120:759–764.
   PubMed Web of Science ®Google Scholar
• Thieblemont C, Felman P, Berger F, et al. Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients. Clin Lymphoma 2002;3:41–7.
   PubMedGoogle Scholar
• Arcaini L, Lazzarino M, Colombo N, et al. Splenic marginal zone lymphoma: a prognostic model for clinical use. Blood 2006;107: 4643–4649.
   PubMed Web of Science ®Google Scholar
• Dungarwalla M, Appiah-Cubi S, Kulkarni S, et al. High-grade transformation in splenic marginal zone lymphoma with circulating villous lymphocytes: the site of transformation influences response to therapy and prognosis. Br J Haematol 2008;143:71–74.
   PubMed Web of Science ®Google Scholar
• Arcaini L, Paulli M, Boveri E, et al. Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic and phenotypic profiles. Cancer 2004;100:107–115.
   PubMed Web of Science ®Google Scholar
• Zibellini S, Capello D, Forconi F, et al. Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma. Haematologica 2010;95:1792–1796.
   PubMed Web of Science ®Google Scholar
• Callet-Bauchu E, Baseggio L, Felman P, et al. Cytogenetic analysis delineates a spectrum of chromosomal changes that can distinguish non-MALT marginal zone B-cell lymphomas among mature B-cell entities: a description of 103 cases. Leukemia 2005;19:1818–1823.
   PubMed Web of Science ®Google Scholar
• Gazzo S, Baseggio L, Coignet L, et al. Cytogenetic and molecular delineation of a region of chromosome 3q commonly gained in marginal zone B-cell lymphoma. Haematologica 2003;88:31–38.
   PubMed Web of Science ®Google Scholar
• Kiel MJ, Velusamy T, Betz BL, et al. Whole-genome sequencing identifies recurrent somatic NOTCH2 mutations in splenic marginal zone lymphoma. J Exp Med 2012;209:1553–1565.
   PubMed Web of Science ®Google Scholar
• Rossi D, Trifonov V, Fangazio M, et al. The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development. J Exp Med 2012;209:1537–1551.
   PubMed Web of Science ®Google Scholar
• Matutes E, Oscier D, Montalban C, et al. Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria. Leukemia 2008;22:487–495.
   PubMed Web of Science ®Google Scholar
• Arcaini L, Burcheri S, Rossi A, et al. Nongastric marginal-zone B-cell MALT lymphoma: prognostic value of disease dissemination. Oncologist 2006;11:285–291.
   PubMed Web of Science ®Google Scholar
• Chacon J, Mollejo M, Munoz E, et al. Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 60 patients. Blood 2002;100:1648–1654.
   PubMed Web of Science ®Google Scholar
• Thieblemont C, Chettab K, Felman P, et al. Identification and validation of 7 genes, as potential markers, for the differential diagnosis of small B-cell lymphomas (lymphocytic B-cell lymphoma, marginal zone lymphoma, mantle cell lymphoma) by cDNA macroarrays analysis. Leukemia 2002;16:2326–2329.
   PubMed Web of Science ®Google Scholar
• Lefrere F, Hermine O, Belanger C, et al. Fludarabine: an effective treatment in patients with splenic lymphoma with villous lymphocytes. Leukemia 2000;14:573–575.
   PubMed Web of Science ®Google Scholar
• Yasukawa M, Yamauchi H, Azuma T, et al. Dramatic efficacy of fludarabine in the treatment of an aggressive case of splenic lymphoma with villous lymphocytes. Eur J Haematol 2002;69:112–114.
   PubMed Web of Science ®Google Scholar
• Iannitto E, Minardi V, Calvaruso G, et al. Deoxycoformycin (pentostatin) in the treatment of splenic marginal zone lymphoma (SMZL) with or without villous lymphocytes. Eur J Haematol 2005;75:130–135.
   PubMed Web of Science ®Google Scholar
• Cervetti G, Galimberti S, Sordi E, et al. Significant efficacy of 2-CdA with or without rituximab in the treatment of splenic marginal zone lymphoma (SMZL). Ann Oncol 2010;21:851–854.
   PubMed Web of Science ®Google Scholar
• Cheson B, Friedberg J, Kahl B, et al. Bendamustine produces durable responses with an acceptable safety profile in patients with rituximab-refractory indolent non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk 2010;10:452–457.
   PubMed Web of Science ®Google Scholar
• Kalpadakis C, Pangalis GA, Dimopoulou MN, et al. Rituximab monotherapy is highly effective in splenic marginal zone lymphoma. Hematol Oncol 2007;25:127–131.
   PubMed Web of Science ®Google Scholar
• Tsimberidou AM, Catovsky D, Schlette E, et al. Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone. Cancer 2006;107:125–135.
   PubMed Web of Science ®Google Scholar
• Bennett M, Sharma K, Yegena S, et al. Rituximab monotherapy for splenic marginal zone lymphoma. Haematologica 2005;90: 856–858.
   PubMed Web of Science ®Google Scholar
• Kalpadakis C, Pangalis GA, Angelopoulou MK, et al. Treatment of splenic marginal zone lymphoma with rituximab monotherapy: progress report and comparison with splenectomy. Oncologist 2013;18:190–197.
   PubMed Web of Science ®Google Scholar
• Arcaini L, Orlandi E, Scotti M, et al. Combination of rituximab, cyclophosphamide, and vincristine induces complete hematologic remission of splenic marginal zone lymphoma. Clin Lymphoma 2004;4:250–252.
   PubMedGoogle Scholar
• Else M, Marín-Niebla A, de la Cruz F, et al. Rituximab, used alone or in combination, is superior to other treatment modalities in splenic marginal zone lymphoma. Br J Haematol 2012;159:322–328.
   PubMed Web of Science ®Google Scholar
• A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987–994.
   PubMed Web of Science ®Google Scholar
• Montalban C, Abraira V, Arcaini L, et al. Simplification of risk stratification for splenic marginal zone lymphoma: a point-based score for practical use. Leuk Lymphoma 2014;55:929–931.
   PubMed Web of Science ®Google Scholar
• Cheson B, Pfistner B, Juweid M, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579–586.
   PubMed Web of Science ®Google Scholar
• Kaplan E, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457–481.
   Web of Science ®Google Scholar
• Iannitto E, Tripodo C. How I diagnose and treat splenic lymphomas. Blood 2011;117:2585–2595.
   PubMed Web of Science ®Google Scholar
• Baccarani U, Donini A, Terrosu G, et al. Laparoscopic splenectomy for haematological diseases: review of current concepts and opinions. Eur J Surg 1999;165:917–923.
   PubMedGoogle Scholar
• Di Sabatino A, Carsetti R, Corazza G. Post-splenectomy and hyposplenic states. Lancet 2011;378:86–97.
   PubMed Web of Science ®Google Scholar
• Bisharat N, Omari H, Lavi I, et al. Risk of infection and death among post-splenectomy patients. J Infect 2001;43:182–186.
   PubMed Web of Science ®Google Scholar
• Holdsworth R, Irving A, Cuschieri A. Postsplenectomy sepsis and its mortality rate: actual versus perceived risks. Br J Surg 1991; 78:1031–1038.
   PubMed Web of Science ®Google Scholar
• Waghorn D. Overwhelming infection in asplenic patients: current best practice preventive measures are not being followed. J Clin Pathol 2001;54:214–218.
   PubMed Web of Science ®Google Scholar
• Troussard X, Valensi F, Duchayne E, et al. Splenic lymphoma with villous lymphocytes: clinical presentation, biology and prognostic factors in a series of 100 patients. Groupe Francais d’Hematologie Cellulaire (GFHC). Br J Haematol 1996;93:731–736.
   Google Scholar
• Camacho FI, Mollejo M, Mateo MS, et al. Progression to large B-cell lymphoma in splenic marginal zone lymphoma - a description of a series of 12 cases. Am J Surg Pathol 2001;25:1268–1276.
   PubMed Web of Science ®Google Scholar
• Franco V, Florena A, Stella M, et al. Splenectomy influences bone marrow infiltration in patients with splenic marginal zone cell lymphoma with or without villous lymphocytes. Cancer 2001;91: 294–301.
   PubMed Web of Science ®Google Scholar